Thymosin-alpha 1 after surgery for high-risk colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial looks at whether thymosin-alpha 1, an immune-support treatment, can help prevent colon cancer from coming back after surgery. It targets people with high-risk stage II or III colon cancer who have had the tumor removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to remove colon cancer completely (radical resection).
- Your cancer was diagnosed as high-risk stage II or stage III.
- Your day-to-day functioning is good (ECOG 0 to 2, meaning you are fully active or limited but not bedridden).
- Your blood counts, liver function, and kidney function are adequate for treatment.
- You have not used immune-promoting medicines before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether additional chemotherapy after surgery can help prevent thymic cancer from coming back. It is for people who have had their thymus tumor completely removed and are in good health.
This trial looks at adding radiation after a complete surgery to remove a thymoma (a tumor from the thymus) at stages II or III. It may help lower the chance the cancer comes back by treating leftover microscopic disease after surgery.
This trial tests giving radiation therapy before surgery for a type of thymus gland tumor (thymoma) that has grown into nearby tissues but has not been treated yet. The goal is to see if this approach can make the tumor removable and improve outcomes.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
This trial tests a new combination of two chemotherapy drugs (CAPOX) plus an immunotherapy drug (tislelizumab) before surgery for high-risk colon cancer that has not spread. It aims to see if adding tislelizumab helps shrink the tumor and lower the chance of the cancer coming back.
Hear when a new Stage II Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.